Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Pfizer (PFE) Financials

Pfizer logo
$24.60 -0.47 (-1.87%)
Closing price 03:59 PM Eastern
Extended Trading
$24.64 +0.04 (+0.18%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Pfizer

Annual Income Statements for Pfizer

This table shows Pfizer's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 9,135 6,960 7,215 21,308 11,153 16,026 9,159 21,979 31,372 2,119 8,031
Consolidated Net Income / (Loss)		 9,168 6,986 7,246 21,355 11,188 16,056 9,195 22,025 31,407 2,158 8,062
Net Income / (Loss) Continuing Operations		 9,119 6,975 7,229 21,353 3,861 10,738 6,666 22,459 31,401 2,172 8,051
Total Pre-Tax Income 		12,240 8,965 8,351 12,305 3,594 11,321 7,036 24,311 34,729 1,058 8,023
Total Operating Income		 13,249 11,824 12,145 13,722 5,672 6,710 8,250 19,433 35,789 1,279 12,411
Total Gross Profit		 40,028 39,203 40,502 41,318 31,838 32,851 33,167 50,467 66,831 34,599 45,776
Total Revenue		 49,605 48,851 52,824 52,546 40,825 40,905 41,651 81,288 101,175 59,553 63,627
Operating Revenue		 49,605 48,851 52,824 52,546 40,825 40,905 41,651 81,288 101,175 59,553 63,627
Total Cost of Revenue		 9,577 9,648 12,322 11,228 8,987 8,054 8,484 30,821 34,344 24,954 17,851
Operating Cost of Revenue		 9,577 9,648 12,322 11,228 8,987 8,054 8,484 30,821 34,344 24,954 17,851
Total Operating Expenses		 26,779 27,379 28,357 27,596 26,166 26,141 24,917 31,034 31,042 33,320 33,365
Selling, General & Admin Expense		 14,097 14,809 14,844 14,804 12,612 12,726 11,597 12,703 13,677 14,771 14,730
Research & Development Expense		 8,393 7,690 7,892 7,683 7,760 8,385 9,393 13,829 12,381 10,873 10,930
Amortization Expense		 4,039 3,728 4,056 4,758 4,736 4,429 3,348 3,700 3,609 4,733 5,286
Restructuring Charge		 250 1,152 1,565 351 1,058 601 579 802 1,375 2,943 2,419
Total Other Income / (Expense), net		 -1,009 -2,860 -3,794 -1,416 -2,077 4,610 -1,213 4,878 -1,062 -222 -4,388
Other Income / (Expense), net		 -1,009 -2,860 -3,794 -1,416 -2,077 -3,497 -1,213 4,878 -1,062 -222 -4,388
Income Tax Expense		 3,120 1,990 1,123 -9,049 -266 583 370 1,852 3,328 -1,115 -28
Net Income / (Loss) Discontinued Operations		 49 11 17 2.00 7,328 5,318 2,529 -434 6.00 -15 11
Net Income / (Loss) Attributable to Noncontrolling Interest		 32 26 31 47 36 29 36 45 35 39 31
Basic Earnings per Share		 $1.44 $1.13 $1.18 $3.57 $1.90 $2.88 $1.65 $3.92 $5.59 $0.38 $1.42
Weighted Average Basic Shares Outstanding		 6.35B 6.18B 6.09B 5.97B 5.87B 5.57B 5.56B 5.60B 5.61B 5.64B 5.66B
Diluted Earnings per Share		 $1.42 $1.11 $1.17 $3.52 $1.87 $2.82 $1.63 $3.85 $5.47 $0.37 $1.41
Weighted Average Diluted Shares Outstanding		 6.42B 6.26B 6.16B 6.06B 5.98B 5.68B 5.63B 5.71B 5.73B 5.71B 5.70B
Weighted Average Basic & Diluted Shares Outstanding		 6.34B 6.18B 6.11B 5.97B 5.87B 5.55B 5.58B 5.62B 5.62B 5.65B 5.67B
Cash Dividends to Common per Share		 $1.04 $1.12 $1.22 - $1.38 $1.46 $1.53 $1.57 $1.61 $1.65 $1.69

Quarterly Income Statements for Pfizer

This table shows Pfizer's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/2/2023 7/2/2023 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/31/2024 3/30/2025 6/29/2025
Net Income / (Loss) Attributable to Common Shareholders		 4,994 5,543 2,327 -2,382 -3,369 3,115 41 4,465 410 2,967 2,910
Consolidated Net Income / (Loss)		 5,003 5,556 2,338 -2,376 -3,360 3,123 48 4,473 418 2,973 2,928
Net Income / (Loss) Continuing Operations		 5,000 5,555 2,340 -2,388 -3,335 3,128 31 4,481 411 2,973 2,903
Total Pre-Tax Income 		5,231 6,270 2,269 -3,352 -4,129 3,421 -103 4,715 -10 2,785 3,044
Total Operating Income		 5,226 6,544 2,194 -3,171 -4,288 4,102 1,003 4,959 2,347 3,738 3,783
Total Gross Profit		 15,485 13,600 9,770 4,222 7,007 11,500 9,983 12,439 11,854 10,870 10,875
Total Revenue		 25,134 18,486 13,007 13,491 14,569 14,879 13,283 17,702 17,763 13,715 14,653
Operating Revenue		 25,134 18,486 13,007 13,491 14,569 14,879 13,283 17,702 17,763 13,715 14,653
Total Cost of Revenue		 9,649 4,886 3,237 9,269 7,562 3,379 3,300 5,263 5,909 2,845 3,778
Operating Cost of Revenue		 9,649 4,886 3,237 9,269 7,562 3,379 3,300 5,263 5,909 2,845 3,778
Total Operating Expenses		 10,259 7,056 7,576 7,393 11,295 7,398 8,980 7,480 9,507 7,132 7,092
Selling, General & Admin Expense		 4,645 3,418 3,497 3,281 4,575 3,495 3,717 3,244 4,274 3,031 3,415
Research & Development Expense		 3,689 2,526 2,681 2,778 2,888 2,493 2,702 2,611 3,124 2,212 2,484
Amortization Expense		 1,130 1,103 1,184 1,179 1,267 1,308 1,307 1,312 1,359 1,211 1,211
Restructuring Charge		 795 9.00 214 155 2,565 102 1,254 313 750 678 -18
Total Other Income / (Expense), net		 1.00 -275 75 -181 159 -680 -1,107 -243 -2,358 -953 -739
Other Income / (Expense), net		 1.00 -275 75 -181 159 -680 -1,107 -243 -2,358 -953 -739
Income Tax Expense		 230 715 -71 -964 -795 293 -134 234 -421 -189 141
Net Income / (Loss) Discontinued Operations		 2.00 1.00 -2.00 12 -26 -5.00 17 -8.00 7.00 0.00 25
Net Income / (Loss) Attributable to Noncontrolling Interest		 8.00 13 11 6.00 9.00 8.00 7.00 8.00 8.00 6.00 18
Basic Earnings per Share		 $0.88 $0.98 $0.41 ($0.42) ($0.59) $0.55 $0.01 $0.79 $0.07 $0.52 $0.51
Weighted Average Basic Shares Outstanding		 5.61B 5.63B 5.65B 5.65B 5.64B 5.66B 5.67B 5.67B 5.66B 5.68B 5.69B
Diluted Earnings per Share		 $0.86 $0.97 $0.41 ($0.42) ($0.59) $0.55 $0.01 $0.78 $0.07 $0.52 $0.51
Weighted Average Diluted Shares Outstanding		 5.73B 5.73B 5.71B 5.65B 5.71B 5.70B 5.70B 5.71B 5.70B 5.71B 5.71B
Weighted Average Basic & Diluted Shares Outstanding		 5.62B 5.65B 5.65B 5.65B 5.65B 5.67B 5.67B 5.67B 5.67B 5.69B 5.69B
Cash Dividends to Common per Share		 - $0.00 $0.82 $0.00 - $0.00 $0.84 $0.00 - $0.00 $0.86

Annual Cash Flow Statements for Pfizer

This table details how cash moves in and out of Pfizer's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1,160 -5,274 -1,042 -1,235 -89 125 475 159 -1,515 2,448 -1,810
Net Cash From Operating Activities		 17,084 14,688 16,192 16,802 15,827 12,588 14,403 32,580 29,267 8,700 12,744
Net Cash From Continuing Operating Activities		 17,082 13,883 16,192 16,800 8,875 7,015 10,540 32,922 29,267 8,701 12,743
Net Income / (Loss) Continuing Operations		 9,168 6,986 7,246 21,355 3,860 10,738 6,666 22,459 31,401 2,172 8,051
Consolidated Net Income / (Loss)		 9,168 6,986 7,246 21,355 11,188 16,056 9,195 22,025 31,407 2,158 8,062
Net Income / (Loss) Discontinued Operations		 - - - - 7,328 5,318 2,529 -434 6.00 -15 11
Depreciation Expense		 5,537 5,157 5,757 6,269 6,150 5,755 4,681 5,191 5,064 6,290 7,013
Non-Cash Adjustments To Reconcile Net Income		 437 1,019 3,091 912 1,402 -5,813 1,077 -3,238 2,205 5,853 2,847
Changes in Operating Assets and Liabilities, net		 1,940 721 98 -11,736 -2,538 -3,664 -1,882 8,511 -9,403 -5,614 -5,168
Net Cash From Investing Activities		 -5,654 -2,980 -7,791 -4,740 4,525 -3,945 -4,271 -22,546 -15,783 -32,278 2,652
Net Cash From Continuing Investing Activities		 -5,654 -8,748 -7,791 -4,740 4,584 -3,825 -4,162 -22,534 -15,783 -32,277 2,654
Purchase of Property, Plant & Equipment		 -1,199 -1,397 -1,823 -1,956 -1,984 -2,046 -2,226 -2,711 -3,236 -3,907 -2,909
Acquisitions		 -579 -16,565 -18,544 -1,261 -152 -10,861 0.00 0.00 -22,997 -43,430 0.00
Purchase of Investments		 -61,672 -38,123 -23,968 -18,133 -17,391 -7,036 -14,402 -39,525 -38,297 -31,178 -10,313
Divestitures		 - - - - - - - - 0.00 0.00 7,040
Sale and/or Maturity of Investments		 57,449 46,993 36,464 15,939 23,825 16,340 12,730 20,008 48,939 46,417 8,834
Other Investing Activities, net		 347 344 80 671 287 -223 -265 -305 -192 -179 2.00
Net Cash From Financing Activities		 -10,187 -10,409 -9,228 -13,350 -20,441 -8,485 -9,649 -9,816 -14,834 26,066 -17,140
Net Cash From Continuing Financing Activities		 -10,187 -10,409 -9,228 -13,349 -20,441 -8,485 -21,640 -9,816 -14,834 26,067 -17,140
Repayment of Debt		 -4,084 -4,129 -13,318 -16,712 -10,208 -15,526 -26,644 -1,988 -7,520 -3,203 -13,945
Repurchase of Common Equity		 -5,000 -6,160 -5,000 -5,000 -12,198 -8,865 0.00 0.00 -2,000 0.00 0.00
Payment of Dividends		 -6,609 -6,940 -7,317 -7,659 -7,978 -8,043 -8,440 -8,729 -8,983 -9,247 -9,512
Issuance of Debt		 4,504 5,557 15,388 15,160 8,685 23,948 13,445 901 3,669 38,517 6,317
Other Net Changes in Cash		 - - -215 53 - -32 -8.00 -59 -165 -40 -66
Cash Interest Paid		 1,550 1,302 1,113 1,319 1,349 1,629 1,621 1,465 1,496 2,349 3,405
Cash Income Taxes Paid		 2,100 2,383 2,521 2,489 3,655 3,664 3,153 7,427 7,867 3,147 3,605

Quarterly Cash Flow Statements for Pfizer

This table details how cash moves in and out of Pfizer's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/2/2023 7/2/2023 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/31/2024 3/30/2025 6/29/2025
Net Change in Cash & Equivalents		 -869 1,754 475 535 -316 -2,137 343 29 -45 375 213
Net Cash From Operating Activities		 8,582 1,212 -1,208 3,456 5,240 1,090 -1,781 6,714 6,721 2,335 -582
Net Cash From Continuing Operating Activities		 8,582 1,211 -1,209 3,458 5,241 1,091 -1,781 6,713 6,720 2,334 -582
Net Income / (Loss) Continuing Operations		 5,001 5,555 2,340 -2,388 -3,335 3,128 31 4,481 411 2,973 2,903
Consolidated Net Income / (Loss)		 5,003 5,556 2,338 -2,376 -3,360 3,123 48 4,473 418 2,973 2,928
Net Income / (Loss) Discontinued Operations		 2.00 1.00 -2.00 12 -26 -5.00 17 -8.00 7.00 0.00 25
Depreciation Expense		 1,519 1,487 1,573 1,560 1,670 1,736 1,731 1,755 1,791 1,618 1,625
Non-Cash Adjustments To Reconcile Net Income		 -15 274 -333 5,598 314 4.00 775 80 1,988 325 151
Changes in Operating Assets and Liabilities, net		 2,077 -6,105 -4,789 -1,312 6,592 -3,777 -4,318 397 2,530 -2,582 -5,261
Net Cash From Investing Activities		 -4,410 3,315 -25,485 888 -10,996 1,732 4,600 -2,057 -1,623 3,274 3,951
Net Cash From Continuing Investing Activities		 -4,411 3,316 -25,486 890 -10,997 1,731 4,601 -2,058 -1,620 3,275 3,948
Purchase of Property, Plant & Equipment		 -1,001 -1,139 -914 -810 -1,044 -704 -637 -651 -917 -564 -618
Purchase of Investments		 -6,969 -6,716 -14,382 -9,206 -874 -832 -530 -2,670 -6,281 -2,957 -3,214
Sale and/or Maturity of Investments		 20,323 11,189 -9,640 10,556 34,312 -224 5,786 1,258 2,014 185 7,792
Other Investing Activities, net		 8.00 -18 -525 350 14 0.00 -18 5.00 15 300 -12
Net Cash From Financing Activities		 -5,015 -2,771 27,174 -3,779 5,442 -4,931 -2,459 -4,636 -5,114 -5,227 -3,196
Net Cash From Continuing Financing Activities		 -5,015 -2,771 27,175 -3,779 5,442 -4,931 -2,459 -4,636 -5,114 -5,227 -3,197
Repayment of Debt		 -1,682 -705 -1,140 -1,337 -21 -1,964 -5,587 -2,928 -3,466 -2,404 -3,922
Payment of Dividends		 -2,245 -2,303 -2,315 -2,314 -2,315 -2,372 -2,380 -2,380 -2,380 -2,437 -2,445
Issuance of Debt		 -1,088 237 30,630 -128 7,778 -595 5,508 672 732 -386 3,170
Other Net Changes in Cash		 -26 -2.00 -5.00 -32 -1.00 -28 -18 9.00 -29 -7.00 41
Cash Interest Paid		 347 479 373 399 1,098 448 1,103 313 1,541 427 1,085
Cash Income Taxes Paid		 2,948 329 1,696 882 240 184 2,502 486 433 152 3,341

Annual Balance Sheets for Pfizer

This table presents Pfizer's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 167,566 167,381 171,615 171,797 159,422 167,594 154,229 181,475 197,205 226,501 213,396
Total Current Assets		 55,595 43,804 38,949 41,142 49,926 32,803 35,067 59,693 51,259 43,333 50,358
Cash & Equivalents		 3,343 3,641 2,595 1,342 1,139 1,121 1,786 1,944 416 2,853 1,043
Short-Term Investments		 32,779 19,649 15,255 18,650 17,694 8,525 10,437 29,125 22,316 9,837 19,434
Accounts Receivable		 8,401 8,176 8,225 8,221 8,025 6,772 7,913 11,479 10,952 11,566 11,463
Inventories, net		 5,663 7,513 6,783 7,578 7,508 7,068 8,020 9,059 8,981 10,189 10,851
Current Deferred & Refundable Income Taxes		 2,566 2,662 3,041 3,050 3,374 2,736 3,264 4,266 3,577 3,978 3,314
Other Current Assets		 2,843 2,154 2,249 2,289 2,461 2,357 3,646 3,820 5,017 4,911 4,253
Plant, Property, & Equipment, net		 11,762 13,766 13,318 13,865 13,385 12,969 13,745 14,882 16,274 18,940 18,393
Total Noncurrent Assets		 100,210 109,811 119,348 116,790 96,112 121,822 105,417 106,900 129,670 164,228 144,644
Long-Term Investments		 17,518 15,999 7,116 7,015 2,767 20,147 20,262 21,526 15,069 15,368 2,227
Goodwill		 42,069 48,242 54,449 55,952 53,411 48,202 49,556 49,208 51,375 67,783 68,527
Intangible Assets		 35,166 40,356 52,648 48,741 35,211 33,936 28,337 25,146 43,370 64,900 55,411
Noncurrent Deferred & Refundable Income Taxes		 1,944 1,794 1,812 1,855 1,924 1,911 2,383 3,341 6,693 3,706 8,662
Other Noncurrent Operating Assets		 3,513 3,420 3,323 3,227 2,799 4,199 4,879 7,679 13,163 12,471 9,817
Total Liabilities & Shareholders' Equity		 167,566 140,505 171,615 171,797 159,422 167,594 154,229 181,476 197,205 226,501 213,396
Total Liabilities		 95,944 75,507 111,775 100,141 95,664 104,148 90,756 104,013 101,288 137,213 124,899
Total Current Liabilities		 21,587 29,399 31,115 30,427 31,858 37,304 25,920 42,671 42,138 47,794 42,995
Short-Term Debt		 5,141 10,159 10,688 9,953 8,831 16,195 2,703 2,241 2,945 10,350 6,946
Accounts Payable		 3,210 3,620 4,536 4,656 4,674 3,887 4,283 5,578 6,809 6,710 5,633
Dividends Payable		 1,711 1,852 1,944 2,029 2,047 2,104 2,162 2,249 2,303 2,372 2,437
Current Deferred Revenue		 - - - - - - 1,113 3,067 2,520 2,700 1,511
Current Deferred & Payable Income Tax Liabilities		 531 418 437 477 1,265 980 1,049 1,266 1,587 2,349 2,910
Current Employee Benefit Liabilities		 1,841 2,359 2,487 2,196 2,397 2,390 3,049 3,332 3,407 2,776 3,838
Other Current Liabilities		 9,153 10,990 11,023 11,115 10,753 9,334 11,561 24,939 22,568 20,537 19,720
Total Noncurrent Liabilities		 74,358 46,108 80,660 69,714 63,806 66,844 64,836 61,342 59,149 89,418 81,904
Long-Term Debt		 31,541 28,740 31,398 33,538 32,909 35,955 37,133 36,195 32,884 61,538 57,405
Noncurrent Deferred & Payable Income Tax Liabilities		 27,670 3,992 34,753 22,597 18,437 17,778 15,623 11,680 10,835 9,174 8,234
Noncurrent Employee Benefit Liabilities		 10,264 8,119 8,172 7,430 6,610 6,217 5,411 3,724 2,250 2,167 2,115
Other Noncurrent Operating Liabilities		 4,883 5,257 6,337 6,149 5,850 6,894 6,669 9,743 13,180 16,539 14,150
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 71,622 64,998 59,840 71,656 63,758 63,447 63,473 77,462 95,916 89,288 88,497
Total Preferred & Common Equity		 71,301 64,720 59,544 71,308 63,407 63,143 63,238 77,200 95,661 89,014 88,203
Total Common Equity		 71,271 64,694 59,520 71,287 63,389 63,125 63,238 77,200 95,661 89,014 88,203
Common Stock		 79,432 81,475 83,146 84,742 86,720 87,896 89,144 91,064 92,278 93,109 94,083
Retained Earnings		 72,176 71,993 71,774 85,291 89,554 97,670 90,392 103,394 125,656 118,353 116,725
Accumulated Other Comprehensive Income / (Loss)		 -7,316 -9,522 -11,036 -9,321 -11,275 -11,640 -5,310 -5,897 -8,304 -7,961 -7,842
Other Equity Adjustments		 - - - - - - - - - - -114,763
Noncontrolling Interest		 321 278 296 348 351 303 235 262 256 274 294

Quarterly Balance Sheets for Pfizer

This table presents Pfizer's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/2/2023 7/2/2023 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/31/2024 3/30/2025 6/29/2025
Total Assets		 197,205 195,617 220,168 215,021 226,501 221,095 216,193 219,476 213,396 208,028 206,095
Total Current Assets		 51,259 50,078 73,347 74,012 43,333 42,415 37,825 43,223 50,358 45,861 43,703
Cash & Equivalents		 416 2,166 2,632 3,148 2,853 719 1,052 1,092 1,043 1,430 1,638
Short-Term Investments		 22,316 17,806 42,153 41,033 9,837 11,209 6,048 8,860 19,434 15,887 11,611
Accounts Receivable		 10,952 12,305 10,231 11,086 11,566 10,989 11,393 14,451 11,463 11,845 12,078
Inventories, net		 8,981 9,541 10,310 10,204 10,189 10,892 11,447 11,721 10,851 10,852 11,669
Current Deferred & Refundable Income Taxes		 3,577 3,140 3,194 3,917 3,978 4,233 3,694 3,243 3,314 2,900 4,016
Other Current Assets		 5,017 5,120 4,828 4,624 4,911 4,372 4,190 3,855 4,253 2,947 2,690
Plant, Property, & Equipment, net		 16,274 17,052 17,488 17,862 18,940 18,803 18,957 18,541 18,393 18,347 18,776
Total Noncurrent Assets		 129,670 128,488 129,333 123,148 164,228 159,878 159,410 157,713 144,644 143,820 143,617
Long-Term Investments		 15,069 14,743 15,066 14,239 15,368 11,613 11,148 10,762 2,227 2,013 2,120
Goodwill		 51,375 51,476 51,572 51,527 67,783 69,297 68,445 68,570 68,527 68,444 68,997
Intangible Assets		 43,370 42,002 41,406 40,224 64,900 62,829 61,240 59,986 55,411 53,976 52,702
Noncurrent Deferred & Refundable Income Taxes		 6,693 7,302 8,261 8,350 3,706 4,942 7,867 7,909 8,662 9,542 10,343
Other Noncurrent Operating Assets		 13,163 12,965 13,028 8,808 12,471 11,197 10,710 10,486 9,817 9,845 9,455
Total Liabilities & Shareholders' Equity		 197,205 195,617 220,168 215,021 226,501 221,095 216,193 219,476 213,396 208,028 206,095
Total Liabilities		 101,288 94,381 120,875 117,817 137,213 128,537 128,218 126,918 124,899 117,391 117,083
Total Current Liabilities		 42,138 36,562 34,647 31,136 47,794 40,497 43,819 43,211 42,995 36,452 37,726
Short-Term Debt		 2,945 4,188 3,985 2,548 10,350 8,232 11,944 9,699 6,946 4,470 4,295
Accounts Payable		 6,809 6,123 6,081 5,338 6,710 5,591 5,106 5,314 5,633 5,240 5,166
Dividends Payable		 2,303 0.00 2,315 0.00 2,372 0.00 2,380 0.00 2,437 0.00 2,445
Current Deferred Revenue		 2,520 1,750 1,286 2,204 2,700 2,502 2,528 2,020 1,511 1,012 1,123
Current Deferred & Payable Income Tax Liabilities		 1,587 1,969 2,928 1,898 2,349 3,192 2,884 2,877 2,910 3,105 3,675
Current Employee Benefit Liabilities		 3,407 2,277 1,972 2,372 2,776 2,192 2,566 3,383 3,838 2,607 2,447
Other Current Liabilities		 22,568 20,255 16,079 16,776 20,537 18,788 16,410 19,917 19,720 20,016 18,575
Total Noncurrent Liabilities		 59,149 57,819 86,227 86,680 89,418 88,039 84,400 83,707 81,904 80,939 79,357
Long-Term Debt		 32,884 31,704 61,356 61,048 61,538 61,307 57,506 58,002 57,405 57,639 57,502
Noncurrent Deferred & Payable Income Tax Liabilities		 10,835 10,927 9,284 9,224 9,174 9,534 8,759 8,063 8,234 7,982 5,794
Noncurrent Employee Benefit Liabilities		 2,250 2,179 2,184 2,166 2,167 2,076 2,040 2,073 2,115 2,021 2,130
Other Noncurrent Operating Liabilities		 13,180 13,009 13,403 14,242 16,539 15,122 16,095 15,569 14,150 13,297 13,931
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 95,916 101,236 99,293 97,204 89,288 92,558 87,975 92,558 88,497 90,637 89,012
Total Preferred & Common Equity		 95,661 100,970 99,019 96,934 89,014 92,282 87,700 92,286 88,203 90,338 88,695
Total Common Equity		 95,661 100,971 99,019 96,934 89,014 92,282 87,700 92,285 88,203 90,338 88,695
Common Stock		 92,278 92,631 92,807 92,974 93,109 93,477 93,677 93,957 94,083 94,337 94,534
Retained Earnings		 125,656 131,102 128,796 126,411 118,353 121,318 116,596 121,059 116,725 119,590 117,609
Treasury Stock		 -113,969 -114,473 -114,482 -114,485 -114,487 -114,755 -114,757 -114,760 -114,763 -115,008 -115,010
Accumulated Other Comprehensive Income / (Loss)		 -8,304 -8,289 -8,102 -7,966 -7,961 -7,758 -7,816 -7,971 -7,842 -8,581 -8,438
Noncontrolling Interest		 256 266 274 270 274 276 275 272 294 299 317

Annual Metrics And Ratios for Pfizer

This table displays calculated financial ratios and metrics derived from Pfizer's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -3.84% -1.52% 8.13% -0.53% -22.30% 0.20% 1.82% 95.16% 24.46% -41.14% 6.84%
EBITDA Growth		 -19.66% -20.57% -0.09% 31.65% -47.53% -7.97% 30.66% 151.77% 34.88% -81.54% 104.66%
EBIT Growth		 -22.12% -26.76% -6.84% 47.34% -70.78% -10.63% 119.02% 245.47% 42.84% -96.96% 659.04%
NOPAT Growth		 -10.45% -6.81% 14.27% 126.50% -74.41% 4.48% 22.81% 129.69% 80.25% -91.88% 374.11%
Net Income Growth		 -58.46% -23.80% 3.72% 194.71% -47.61% 43.51% -42.73% 139.53% 42.60% -93.13% 273.59%
EPS Growth		 -55.49% -21.83% 5.41% 200.85% -46.88% 50.80% -42.20% 136.20% 42.08% -93.24% 281.08%
Operating Cash Flow Growth		 -3.39% -14.02% 10.24% 3.77% -5.80% -20.47% 14.42% 126.20% -10.17% -70.27% 46.48%
Free Cash Flow Firm Growth		 30.69% -242.66% 192.73% -54.33% 54.30% -34.91% -36.47% 238.44% -93.44% -2,300.11% 141.96%
Invested Capital Growth		 -14.53% 65.55% -16.31% 15.43% -13.36% -6.97% 0.43% -10.19% 46.83% 40.78% -2.15%
Revenue Q/Q Growth		 -0.88% 1.94% -0.79% 0.14% -23.51% 1.71% 29.89% 18.02% 1.30% -14.03% 7.16%
EBITDA Q/Q Growth		 -6.02% -12.76% 9.79% 1.09% -51.52% 13.56% 260.78% 13.16% 4.20% -55.61% 39.26%
EBIT Q/Q Growth		 -7.41% -19.40% 15.70% 1.45% -73.92% 72.37% 583.98% 15.18% 4.26% -89.85% 105.45%
NOPAT Q/Q Growth		 -3.94% 0.37% -1.43% 123.11% -74.84% 26.28% 326.34% 12.83% 7.27% -73.82% 139.28%
Net Income Q/Q Growth		 -12.73% -16.75% 15.07% 116.89% -53.09% -1.22% 18.42% 13.00% 5.41% -79.49% 88.19%
EPS Q/Q Growth		 -14.97% -16.54% 15.84% 117.28% -52.78% -1.74% 18.98% 12.90% 5.19% -79.67% 88.00%
Operating Cash Flow Q/Q Growth		 -0.73% -4.56% 7.60% 6.65% -12.93% -7.15% 14.79% 0.90% 10.03% -27.75% 13.15%
Free Cash Flow Firm Q/Q Growth		 306.13% -7,467.04% 336.40% -73.37% 13.74% 210.05% 77.99% -34.91% -88.99% -247.07% 148.08%
Invested Capital Q/Q Growth		 -33.75% -1.38% -32.77% 9.00% -14.15% -21.19% -18.75% -1.79% 17.66% 32.34% -4.99%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 80.69% 80.25% 76.67% 78.63% 77.99% 80.31% 79.63% 62.08% 66.05% 58.10% 71.94%
EBITDA Margin		 35.84% 28.91% 26.71% 35.35% 23.87% 21.92% 28.13% 36.29% 39.33% 12.34% 23.63%
Operating Margin		 26.71% 24.20% 22.99% 26.11% 13.89% 16.40% 19.81% 23.91% 35.37% 2.15% 19.51%
EBIT Margin		 24.67% 18.35% 15.81% 23.42% 8.81% 7.85% 16.90% 29.91% 34.32% 1.77% 12.61%
Profit (Net Income) Margin		 18.48% 14.30% 13.72% 40.64% 27.40% 39.25% 22.08% 27.10% 31.04% 3.62% 12.67%
Tax Burden Percent		 74.90% 77.93% 86.77% 173.55% 311.30% 141.82% 130.69% 90.60% 90.43% 203.97% 100.49%
Interest Burden Percent		 100.00% 100.01% 100.00% 100.01% 99.97% 352.35% 99.99% 100.00% 100.01% 100.09% 100.00%
Effective Tax Rate		 25.49% 22.20% 13.45% -73.54% -7.40% 5.15% 5.26% 7.62% 9.58% -105.39% -0.35%
Return on Invested Capital (ROIC)		 16.14% 12.29% 12.26% 28.30% 7.24% 8.44% 10.73% 25.92% 40.00% 2.27% 9.29%
ROIC Less NNEP Spread (ROIC-NNEP)		 21.57% -21.55% -1.75% 14.95% 38.26% 90.65% 25.45% -313.59% 56.45% 0.25% -0.44%
Return on Net Nonoperating Assets (RNNOA)		 -3.77% -2.06% -0.66% 4.18% 9.28% 16.80% 3.76% 5.34% -3.77% 0.06% -0.22%
Return on Equity (ROE)		 12.37% 10.23% 11.61% 32.48% 16.52% 25.24% 14.49% 31.26% 36.23% 2.33% 9.07%
Cash Return on Invested Capital (CROIC)		 31.81% -37.08% 30.03% 13.97% 21.56% 15.66% 10.30% 36.65% 2.06% -31.60% 11.46%
Operating Return on Assets (OROA)		 7.21% 5.35% 4.93% 7.17% 2.17% 1.97% 4.37% 14.48% 18.34% 0.50% 3.65%
Return on Assets (ROA)		 5.40% 4.17% 4.28% 12.44% 6.76% 9.82% 5.71% 13.12% 16.59% 1.02% 3.67%
Return on Common Equity (ROCE)		 12.31% 10.18% 11.55% 32.31% 16.43% 25.11% 14.43% 31.15% 36.12% 2.32% 9.04%
Return on Equity Simple (ROE_SIMPLE)		 12.86% 10.79% 12.17% 29.95% 17.64% 25.43% 14.54% 28.53% 32.83% 2.42% 9.14%
Net Operating Profit after Tax (NOPAT)		 9,872 9,199 10,512 23,810 6,092 6,364 7,816 17,953 32,359 2,627 12,454
NOPAT Margin		 19.90% 18.83% 19.90% 45.31% 14.92% 15.56% 18.77% 22.09% 31.98% 4.41% 19.57%
Net Nonoperating Expense Percent (NNEP)		 -5.43% 33.84% 14.02% 13.35% -31.02% -82.21% -14.72% 339.51% -16.45% 2.02% 9.73%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 24.56% 1.63% 8.15%
Cost of Revenue to Revenue		 19.31% 19.75% 23.33% 21.37% 22.01% 19.69% 20.37% 37.92% 33.95% 41.90% 28.06%
SG&A Expenses to Revenue		 28.42% 30.31% 28.10% 28.17% 30.89% 31.11% 27.84% 15.63% 13.52% 24.80% 23.15%
R&D to Revenue		 16.92% 15.74% 14.94% 14.62% 19.01% 20.50% 22.55% 17.01% 12.24% 18.26% 17.18%
Operating Expenses to Revenue		 53.98% 56.05% 53.68% 52.52% 64.09% 63.91% 59.82% 38.18% 30.68% 55.95% 52.44%
Earnings before Interest and Taxes (EBIT)		 12,240 8,964 8,351 12,304 3,595 3,213 7,037 24,311 34,727 1,057 8,023
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 17,777 14,121 14,108 18,573 9,745 8,968 11,718 29,502 39,791 7,347 15,036
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.89 2.18 2.43 2.31 3.15 2.82 2.76 3.81 2.67 1.69 1.68
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 103.26 278.47 0.00 0.00
Price to Revenue (P/Rev)		 2.71 2.89 2.74 3.14 4.89 4.35 4.19 3.62 2.52 2.53 2.32
Price to Earnings (P/E)		 14.71 20.26 20.06 7.73 17.88 11.09 19.06 13.37 8.13 71.12 18.42
Dividend Yield		 4.88% 4.90% 5.03% 4.63% 3.94% 4.48% 4.84% 2.98% 3.52% 6.14% 6.44%
Earnings Yield		 6.80% 4.94% 4.99% 12.93% 5.59% 9.02% 5.25% 7.48% 12.30% 1.41% 5.43%
Enterprise Value to Invested Capital (EV/IC)		 2.09 1.51 2.08 2.01 2.82 2.76 2.50 4.27 2.63 1.44 1.43
Enterprise Value to Revenue (EV/Rev)		 2.37 2.88 3.07 3.46 5.39 4.90 4.37 3.44 2.50 3.27 2.98
Enterprise Value to EBITDA (EV/EBITDA)		 6.63 9.98 11.50 9.78 22.57 22.35 15.55 9.49 6.37 26.52 12.63
Enterprise Value to EBIT (EV/EBIT)		 9.62 15.72 19.42 14.76 61.18 62.38 25.89 11.52 7.30 184.30 23.66
Enterprise Value to NOPAT (EV/NOPAT)		 11.93 15.32 15.43 7.63 36.11 31.49 23.31 15.60 7.83 74.16 15.24
Enterprise Value to Operating Cash Flow (EV/OCF)		 6.89 9.59 10.02 10.81 13.90 15.92 12.65 8.59 8.66 22.39 14.90
Enterprise Value to Free Cash Flow (EV/FCFF)		 6.05 0.00 6.30 15.45 12.13 16.98 24.29 11.03 152.22 0.00 12.35
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.51 0.60 0.70 0.61 0.65 0.82 0.63 0.50 0.37 0.81 0.73
Long-Term Debt to Equity		 0.44 0.44 0.52 0.47 0.52 0.57 0.59 0.47 0.34 0.69 0.65
Financial Leverage		 -0.17 0.10 0.37 0.28 0.24 0.19 0.15 -0.02 -0.07 0.25 0.51
Leverage Ratio		 2.29 2.45 2.72 2.61 2.45 2.57 2.54 2.38 2.18 2.29 2.47
Compound Leverage Factor		 2.29 2.45 2.72 2.61 2.45 9.06 2.54 2.38 2.18 2.29 2.47
Debt to Total Capital		 33.87% 37.44% 41.29% 37.77% 39.56% 45.11% 38.56% 33.16% 27.20% 44.60% 42.10%
Short-Term Debt to Total Capital		 4.75% 9.78% 10.49% 8.64% 8.37% 14.01% 2.62% 1.93% 2.24% 6.42% 4.54%
Long-Term Debt to Total Capital		 29.12% 27.66% 30.80% 29.13% 31.19% 31.10% 35.94% 31.23% 24.96% 38.18% 37.56%
Preferred Equity to Total Capital		 0.03% 0.03% 0.02% 0.02% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.30% 0.27% 0.29% 0.30% 0.33% 0.26% 0.23% 0.23% 0.19% 0.17% 0.19%
Common Equity to Total Capital		 65.81% 62.27% 58.40% 61.91% 60.08% 54.61% 61.21% 66.61% 72.61% 55.23% 57.71%
Debt to EBITDA		 2.06 2.75 2.98 2.34 4.28 5.82 3.40 1.30 0.90 9.78 4.28
Net Debt to EBITDA		 -0.95 -0.03 1.21 0.89 2.07 2.49 0.63 -0.48 -0.05 5.97 2.77
Long-Term Debt to EBITDA		 1.77 2.04 2.23 1.81 3.38 4.01 3.17 1.23 0.83 8.38 3.82
Debt to NOPAT		 3.72 4.23 4.00 1.83 6.85 8.19 5.10 2.14 1.11 27.37 5.17
Net Debt to NOPAT		 -1.72 -0.04 1.63 0.69 3.31 3.51 0.94 -0.79 -0.06 16.69 3.34
Long-Term Debt to NOPAT		 3.20 3.12 2.99 1.41 5.40 5.65 4.75 2.02 1.02 23.43 4.61
Altman Z-Score		 2.22 2.29 1.89 2.30 2.50 2.12 2.47 3.50 3.55 1.65 1.94
Noncontrolling Interest Sharing Ratio		 0.47% 0.48% 0.50% 0.52% 0.55% 0.54% 0.44% 0.35% 0.30% 0.29% 0.32%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.58 1.49 1.25 1.35 1.57 0.88 1.35 1.40 1.22 0.91 1.17
Quick Ratio		 2.06 1.07 0.84 0.93 0.84 0.44 0.78 1.00 0.80 0.51 0.74
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 19,455 -27,754 25,737 11,755 18,138 11,806 7,501 25,387 1,664 -36,619 15,366
Operating Cash Flow to CapEx		 1,424.85% 1,051.40% 888.21% 859.00% 797.73% 615.25% 647.04% 1,201.77% 904.42% 222.68% 438.09%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.29 0.29 0.31 0.31 0.25 0.25 0.26 0.48 0.53 0.28 0.29
Accounts Receivable Turnover		 5.59 5.89 6.44 6.39 5.03 5.53 5.67 8.38 9.02 5.29 5.53
Inventory Turnover		 1.62 1.46 1.72 1.56 1.19 1.11 1.12 3.61 3.81 2.60 1.70
Fixed Asset Turnover		 4.11 3.83 3.90 3.87 3.00 3.10 3.12 5.68 6.49 3.38 3.41
Accounts Payable Turnover		 2.97 2.83 3.02 2.44 1.93 1.88 2.08 6.25 5.55 3.69 2.89
Days Sales Outstanding (DSO)		 65.33 61.93 56.66 57.12 72.62 66.02 64.34 43.54 40.46 69.01 66.05
Days Inventory Outstanding (DIO)		 225.41 249.24 211.74 233.42 306.35 330.29 324.56 101.13 95.86 140.20 215.10
Days Payable Outstanding (DPO)		 122.80 129.20 120.80 149.41 189.47 193.99 175.75 58.39 65.82 98.87 126.19
Cash Conversion Cycle (CCC)		 167.95 181.97 147.60 141.14 189.51 202.31 213.16 86.28 70.50 110.33 154.97
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 56,375 93,328 78,103 90,158 78,112 72,670 72,985 65,551 96,246 135,492 132,580
Invested Capital Turnover		 0.81 0.65 0.62 0.62 0.49 0.54 0.57 1.17 1.25 0.51 0.47
Increase / (Decrease) in Invested Capital		 -9,583 36,953 -15,225 12,055 -12,046 -5,442 315 -7,434 30,695 39,246 -2,912
Enterprise Value (EV)		 117,774 140,905 162,174 181,627 219,960 200,436 182,177 279,990 253,360 194,808 189,841
Market Capitalization		 134,382 140,991 144,734 164,774 199,450 177,759 174,591 293,887 255,076 150,704 147,900
Book Value per Share		 $11.31 $10.48 $9.81 $11.96 $10.97 $11.41 $11.38 $13.75 $17.04 $15.76 $15.56
Tangible Book Value per Share		 ($0.95) ($3.87) ($7.84) ($5.60) ($4.37) ($3.44) ($2.64) $0.51 $0.16 ($7.73) ($6.31)
Total Capital		 108,304 103,897 101,926 115,147 105,498 115,597 103,309 115,898 131,745 161,176 152,848
Total Debt		 36,682 38,899 42,086 43,491 41,740 52,150 39,836 38,436 35,829 71,888 64,351
Total Long-Term Debt		 31,541 28,740 31,398 33,538 32,909 35,955 37,133 36,195 32,884 61,538 57,405
Net Debt		 -16,958 -390 17,120 16,484 20,140 22,357 7,351 -14,159 -1,972 43,830 41,647
Capital Expenditures (CapEx)		 1,199 1,397 1,823 1,956 1,984 2,046 2,226 2,711 3,236 3,907 2,909
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3,027 1,274 672 676 8,066 2,048 -373 -11,806 -10,666 -6,801 -6,168
Debt-free Net Working Capital (DFNWC)		 39,149 24,564 18,522 20,668 26,899 11,694 11,850 19,263 12,066 5,889 14,309
Net Working Capital (NWC)		 34,008 14,405 7,834 10,715 18,068 -4,501 9,147 17,022 9,121 -4,461 7,363
Net Nonoperating Expense (NNE)		 704 2,213 3,266 2,455 -5,096 -9,692 -1,379 -4,072 952 469 4,392
Net Nonoperating Obligations (NNO)		 -15,247 28,330 18,263 18,502 14,354 9,223 9,512 -11,911 330 46,204 44,083
Total Depreciation and Amortization (D&A)		 5,537 5,157 5,757 6,269 6,150 5,755 4,681 5,191 5,064 6,290 7,013
Debt-free, Cash-free Net Working Capital to Revenue		 6.10% 2.61% 1.27% 1.29% 19.76% 5.01% -0.90% -14.52% -10.54% -11.42% -9.69%
Debt-free Net Working Capital to Revenue		 78.92% 50.28% 35.06% 39.33% 65.89% 28.59% 28.45% 23.70% 11.93% 9.89% 22.49%
Net Working Capital to Revenue		 68.56% 29.49% 14.83% 20.39% 44.26% -11.00% 21.96% 20.94% 9.02% -7.49% 11.57%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.44 $1.13 $1.18 $3.57 $1.90 $2.92 $1.73 $3.92 $5.59 $0.38 $1.42
Adjusted Weighted Average Basic Shares Outstanding		 6.35B 6.18B 6.09B 5.97B 5.87B 5.57B 5.56B 5.60B 5.61B 5.64B 5.66B
Adjusted Diluted Earnings per Share		 $1.42 $1.11 $1.17 $3.52 $1.87 $2.87 $1.71 $3.85 $5.47 $0.37 $1.41
Adjusted Weighted Average Diluted Shares Outstanding		 6.42B 6.26B 6.16B 6.06B 5.98B 5.68B 5.63B 5.71B 5.73B 5.71B 5.70B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $2.92 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.13B 6.18B 5.95B 5.95B 5.55B 5.55B 5.58B 5.62B 5.62B 5.65B 5.67B
Normalized Net Operating Profit after Tax (NOPAT)		 10,058 10,096 11,866 9,850 4,711 6,935 8,365 18,694 33,603 2,955 10,381
Normalized NOPAT Margin		 20.28% 20.67% 22.46% 18.75% 11.54% 16.95% 20.08% 23.00% 33.21% 4.96% 16.32%
Pre Tax Income Margin		 24.67% 18.35% 15.81% 23.42% 8.80% 27.68% 16.89% 29.91% 34.33% 1.78% 12.61%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 72.09% 99.34% 100.98% 35.87% 71.31% 50.09% 91.79% 39.63% 28.60% 428.50% 117.99%
Augmented Payout Ratio		 126.63% 187.52% 169.98% 59.28% 180.34% 105.31% 91.79% 39.63% 34.97% 428.50% 117.99%

Quarterly Metrics And Ratios for Pfizer

This table displays calculated financial ratios and metrics derived from Pfizer's official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 4/2/2023 7/2/2023 10/1/2023 12/31/2023 3/31/2024 6/30/2024 9/29/2024 12/31/2024 3/30/2025 6/29/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 5.44% -27.96% -53.11% -40.41% -42.03% -19.51% 2.12% 31.21% 21.92% -7.82% 10.31%
EBITDA Growth		 31.19% -24.24% -69.56% -117.59% -136.45% -33.50% -57.65% 461.10% 172.39% -14.64% 186.97%
EBIT Growth		 37.30% -30.74% -80.18% -137.24% -178.99% -45.41% -104.58% 240.69% 99.73% -18.61% 3,026.92%
NOPAT Growth		 79.81% -29.15% -78.54% -125.84% -160.08% -35.31% -68.97% 312.32% 154.73% 6.43% 413.85%
Net Income Growth		 47.54% -29.40% -76.41% -127.55% -167.16% -43.79% -97.95% 288.26% 112.44% -4.80% 6,000.00%
EPS Growth		 45.76% -29.20% -76.30% -127.81% -168.60% -43.30% -97.56% 285.71% 111.86% -5.45% 5,000.00%
Operating Cash Flow Growth		 45.11% -81.47% -114.79% -42.15% -38.94% -10.07% -47.43% 94.27% 28.26% 114.22% 67.32%
Free Cash Flow Firm Growth		 -351.64% -361.82% -1,519.09% -252.76% -64.40% -45.49% -24.52% -42.30% 110.78% 128.19% 121.56%
Invested Capital Growth		 46.83% 37.74% 37.78% 25.17% 40.78% 35.29% 32.17% 36.30% -2.15% -3.71% -2.59%
Revenue Q/Q Growth		 11.03% -23.89% -29.64% 3.72% 7.99% 8.05% -10.73% 33.27% 0.34% -22.79% 6.84%
EBITDA Q/Q Growth		 -33.77% 14.97% -50.46% -146.64% -37.22% 309.67% -68.46% 297.73% -72.49% 147.36% 6.04%
EBIT Q/Q Growth		 -41.94% 19.94% -63.81% -247.73% -23.18% 182.86% -103.04% 4,634.62% -100.23% 25,418.18% 9.30%
NOPAT Q/Q Growth		 -41.83% 38.43% -60.97% -198.10% -35.23% 205.35% -81.28% 571.26% -65.14% 142.97% -9.62%
Net Income Q/Q Growth		 -41.98% 11.05% -57.92% -201.63% -41.41% 192.95% -98.46% 9,218.75% -90.66% 611.24% -1.51%
EPS Q/Q Growth		 -43.05% 12.79% -57.73% -202.44% -40.48% 193.22% -98.18% 7,700.00% -91.03% 642.86% -1.92%
Operating Cash Flow Q/Q Growth		 43.66% -85.88% -199.67% 386.09% 51.62% -79.20% -263.39% 476.98% 0.10% -65.26% -124.93%
Free Cash Flow Firm Q/Q Growth		 -297.52% 16.01% -21.75% 15.87% -85.26% 24.33% -4.20% 3.85% 114.04% 100.46% -20.29%
Invested Capital Q/Q Growth		 17.66% 6.41% 4.58% -4.41% 32.34% 2.26% 2.16% -1.42% -4.99% 0.63% 3.35%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 61.61% 73.57% 75.11% 31.29% 48.10% 77.29% 75.16% 70.27% 66.73% 79.26% 74.22%
EBITDA Margin		 26.84% 41.96% 29.54% -13.28% -16.88% 34.67% 12.25% 36.56% 10.02% 32.10% 31.86%
Operating Margin		 20.79% 35.40% 16.87% -23.50% -29.43% 27.57% 7.55% 28.01% 13.21% 27.25% 25.82%
EBIT Margin		 20.80% 33.91% 17.44% -24.85% -28.34% 23.00% -0.78% 26.64% -0.06% 20.31% 20.77%
Profit (Net Income) Margin		 19.91% 30.06% 17.97% -17.61% -23.06% 20.99% 0.36% 25.27% 2.35% 21.68% 19.98%
Tax Burden Percent		 95.64% 88.61% 103.04% 70.88% 81.38% 91.29% -46.60% 94.87% -4,180.00% 106.75% 96.19%
Interest Burden Percent		 100.08% 100.02% 100.00% 100.00% 100.00% 99.97% 99.04% 99.98% 90.91% 100.00% 100.00%
Effective Tax Rate		 4.40% 11.40% -3.13% 0.00% 0.00% 8.56% 0.00% 4.96% 0.00% -6.79% 4.63%
Return on Invested Capital (ROIC)		 24.86% 33.06% 14.76% -12.38% -10.59% 11.48% 2.35% 13.07% 4.39% 13.37% 11.25%
ROIC Less NNEP Spread (ROIC-NNEP)		 24.74% 39.81% 6.95% -7.09% -12.13% 8.82% 0.21% 12.15% 1.68% 11.07% 9.92%
Return on Net Nonoperating Assets (RNNOA)		 -1.65% -1.55% -0.07% 0.22% -3.05% 2.15% 0.07% 3.34% 0.85% 5.37% 5.74%
Return on Equity (ROE)		 23.21% 31.51% 14.69% -12.16% -13.64% 13.63% 2.42% 16.41% 5.24% 18.74% 16.99%
Cash Return on Invested Capital (CROIC)		 2.06% 1.29% -9.20% -11.46% -31.60% -31.29% -29.63% -26.42% 11.46% 13.25% 13.48%
Operating Return on Assets (OROA)		 11.11% 16.65% 6.59% -8.39% -7.97% 6.06% -0.20% 7.28% -0.02% 5.91% 6.28%
Return on Assets (ROA)		 10.64% 14.76% 6.79% -5.95% -6.48% 5.53% 0.09% 6.91% 0.68% 6.31% 6.04%
Return on Common Equity (ROCE)		 23.14% 31.42% 14.65% -12.12% -13.60% 13.59% 2.41% 16.36% 5.23% 18.68% 16.94%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 28.81% 21.73% 10.85% 0.00% -0.30% -2.92% 4.64% 0.00% 8.76% 0.00%
Net Operating Profit after Tax (NOPAT)		 4,996 5,798 2,263 -2,220 -3,002 3,751 702 4,713 1,643 3,992 3,608
NOPAT Margin		 19.88% 31.36% 17.40% -16.45% -20.60% 25.21% 5.29% 26.62% 9.25% 29.10% 24.62%
Net Nonoperating Expense Percent (NNEP)		 0.12% -6.76% 7.81% -5.28% 1.54% 2.66% 2.13% 0.92% 2.71% 2.29% 1.33%
Return On Investment Capital (ROIC_SIMPLE)		 3.79% - - - -1.86% - - - 1.07% 2.61% 2.39%
Cost of Revenue to Revenue		 38.39% 26.43% 24.89% 68.71% 51.90% 22.71% 24.84% 29.73% 33.27% 20.74% 25.78%
SG&A Expenses to Revenue		 18.48% 18.49% 26.89% 24.32% 31.40% 23.49% 27.98% 18.33% 24.06% 22.10% 23.31%
R&D to Revenue		 14.68% 13.66% 20.61% 20.59% 19.82% 16.76% 20.34% 14.75% 17.59% 16.13% 16.95%
Operating Expenses to Revenue		 40.82% 38.17% 58.25% 54.80% 77.53% 49.72% 67.61% 42.26% 53.52% 52.00% 48.40%
Earnings before Interest and Taxes (EBIT)		 5,227 6,269 2,269 -3,352 -4,129 3,422 -104 4,716 -11 2,785 3,044
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 6,746 7,756 3,842 -1,792 -2,459 5,158 1,627 6,471 1,780 4,403 4,669
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.67 2.10 1.95 1.82 1.69 1.65 1.78 1.79 1.68 1.58 1.52
Price to Tangible Book Value (P/TBV)		 278.47 28.27 32.01 34.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.52 2.27 2.47 2.55 2.53 2.77 2.83 2.78 2.32 2.29 2.12
Price to Earnings (P/E)		 8.13 7.29 9.01 16.87 71.12 0.00 0.00 38.77 18.42 18.12 12.57
Dividend Yield		 3.52% 4.27% 4.73% 5.20% 6.14% 6.12% 6.02% 5.74% 6.44% 6.70% 7.15%
Earnings Yield		 12.30% 13.72% 11.10% 5.93% 1.41% 0.00% 0.00% 2.58% 5.43% 5.52% 7.95%
Enterprise Value to Invested Capital (EV/IC)		 2.63 2.08 1.86 1.78 1.44 1.43 1.47 1.52 1.43 1.39 1.32
Enterprise Value to Revenue (EV/Rev)		 2.50 2.29 2.54 2.63 3.27 3.62 3.77 3.57 2.98 2.98 2.85
Enterprise Value to EBITDA (EV/EBITDA)		 6.37 5.72 6.98 11.01 26.52 41.80 82.01 19.64 12.63 13.02 10.50
Enterprise Value to EBIT (EV/EBIT)		 7.30 6.68 8.75 17.51 184.30 0.00 0.00 54.32 23.66 25.18 17.27
Enterprise Value to NOPAT (EV/NOPAT)		 7.83 7.30 9.54 18.17 74.16 0.00 0.00 40.75 15.24 14.44 12.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.66 8.91 13.68 15.14 22.39 23.14 25.96 18.83 14.90 13.29 11.98
Enterprise Value to Free Cash Flow (EV/FCFF)		 152.22 186.80 0.00 0.00 0.00 0.00 0.00 0.00 12.35 10.32 9.66
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.37 0.35 0.66 0.65 0.81 0.75 0.79 0.73 0.73 0.69 0.69
Long-Term Debt to Equity		 0.34 0.31 0.62 0.63 0.69 0.66 0.65 0.63 0.65 0.64 0.65
Financial Leverage		 -0.07 -0.04 -0.01 -0.03 0.25 0.24 0.33 0.27 0.51 0.48 0.58
Leverage Ratio		 2.18 2.06 2.22 2.16 2.29 2.15 2.33 2.29 2.47 2.34 2.39
Compound Leverage Factor		 2.19 2.06 2.22 2.16 2.29 2.15 2.31 2.29 2.25 2.34 2.39
Debt to Total Capital		 27.20% 26.17% 39.69% 39.55% 44.60% 42.90% 44.12% 42.24% 42.10% 40.66% 40.98%
Short-Term Debt to Total Capital		 2.24% 3.05% 2.42% 1.58% 6.42% 5.08% 7.59% 6.05% 4.54% 2.93% 2.85%
Long-Term Debt to Total Capital		 24.96% 23.12% 37.27% 37.97% 38.18% 37.82% 36.53% 36.19% 37.56% 37.74% 38.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.19% 0.19% 0.17% 0.17% 0.17% 0.17% 0.17% 0.17% 0.19% 0.20% 0.21%
Common Equity to Total Capital		 72.61% 73.63% 60.14% 60.28% 55.23% 56.93% 55.71% 57.58% 57.71% 59.14% 58.81%
Debt to EBITDA		 0.90 0.96 2.29 3.84 9.78 14.64 27.41 6.27 4.28 4.35 3.57
Net Debt to EBITDA		 -0.05 0.03 0.19 0.31 5.97 9.69 20.21 4.35 2.77 3.00 2.68
Long-Term Debt to EBITDA		 0.83 0.85 2.15 3.69 8.38 12.91 22.69 5.37 3.82 4.04 3.32
Debt to NOPAT		 1.11 1.23 3.13 6.34 27.37 -44.75 -29.09 13.01 5.17 4.82 4.08
Net Debt to NOPAT		 -0.06 0.04 0.26 0.52 16.69 -29.60 -21.44 9.03 3.34 3.32 3.06
Long-Term Debt to NOPAT		 1.02 1.09 2.94 6.08 23.43 -39.45 -24.08 11.14 4.61 4.48 3.79
Altman Z-Score		 3.06 2.95 2.38 2.23 1.57 1.79 1.71 1.89 1.82 1.93 1.89
Noncontrolling Interest Sharing Ratio		 0.30% 0.29% 0.29% 0.28% 0.29% 0.28% 0.29% 0.29% 0.32% 0.31% 0.33%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.22 1.37 2.12 2.38 0.91 1.05 0.86 1.00 1.17 1.26 1.16
Quick Ratio		 0.80 0.88 1.59 1.78 0.51 0.57 0.42 0.56 0.74 0.80 0.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25,699 -22,264 -27,106 -22,805 -42,248 -32,392 -33,752 -32,451 4,555 9,131 7,278
Operating Cash Flow to CapEx		 857.34% 106.41% -132.17% 426.67% 501.92% 154.83% -279.59% 1,031.34% 732.93% 414.01% -94.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.53 0.49 0.38 0.34 0.28 0.26 0.25 0.27 0.29 0.29 0.30
Accounts Receivable Turnover		 9.02 7.30 6.18 5.10 5.29 4.71 5.10 4.65 5.53 5.47 5.44
Inventory Turnover		 3.81 3.00 2.30 2.74 2.60 2.30 2.16 1.78 1.70 1.59 1.54
Fixed Asset Turnover		 6.49 5.79 4.79 4.16 3.38 3.06 3.03 3.26 3.41 3.36 3.38
Accounts Payable Turnover		 5.55 5.03 3.88 4.66 3.69 4.00 4.20 3.66 2.89 3.20 3.46
Days Sales Outstanding (DSO)		 40.46 50.02 59.08 71.56 69.01 77.45 71.54 78.49 66.05 66.71 67.10
Days Inventory Outstanding (DIO)		 95.86 121.81 158.99 133.07 140.20 159.04 168.89 205.15 215.10 229.16 237.07
Days Payable Outstanding (DPO)		 65.82 72.57 94.09 78.32 98.87 91.18 86.84 99.67 126.19 114.15 105.35
Cash Conversion Cycle (CCC)		 70.50 99.26 123.97 126.31 110.33 145.31 153.59 183.97 154.97 181.72 198.83
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 96,246 102,414 107,101 102,382 135,492 138,557 141,555 139,546 132,580 133,418 137,885
Invested Capital Turnover		 1.25 1.05 0.85 0.75 0.51 0.46 0.44 0.49 0.47 0.46 0.46
Increase / (Decrease) in Invested Capital		 30,695 28,062 29,369 20,585 39,246 36,143 34,454 37,164 -2,912 -5,139 -3,670
Enterprise Value (EV)		 253,360 213,254 199,146 182,291 194,808 198,486 207,822 212,103 189,841 185,952 181,941
Market Capitalization		 255,076 211,811 193,382 176,845 150,704 152,212 156,345 164,844 147,900 142,874 135,196
Book Value per Share		 $17.04 $17.97 $17.54 $17.17 $15.76 $16.31 $15.48 $16.29 $15.56 $15.94 $15.60
Tangible Book Value per Share		 $0.16 $1.33 $1.07 $0.92 ($7.73) ($7.04) ($7.41) ($6.40) ($6.31) ($5.66) ($5.81)
Total Capital		 131,745 137,128 164,634 160,800 161,176 162,097 157,425 160,259 152,848 152,746 150,809
Total Debt		 35,829 35,892 65,341 63,596 71,888 69,539 69,450 67,701 64,351 62,109 61,797
Total Long-Term Debt		 32,884 31,704 61,356 61,048 61,538 61,307 57,506 58,002 57,405 57,639 57,502
Net Debt		 -1,972 1,177 5,490 5,176 43,830 45,998 51,202 46,987 41,647 42,779 46,428
Capital Expenditures (CapEx)		 1,001 1,139 914 810 1,044 704 637 651 917 564 618
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -10,666 -2,268 -2,100 1,243 -6,801 -1,778 -1,150 -241 -6,168 -3,438 -2,977
Debt-free Net Working Capital (DFNWC)		 12,066 17,704 42,685 45,424 5,889 10,150 5,950 9,711 14,309 13,879 10,272
Net Working Capital (NWC)		 9,121 13,516 38,700 42,876 -4,461 1,918 -5,994 12 7,363 9,409 5,977
Net Nonoperating Expense (NNE)		 -6.78 242 -75 156 358 628 654 240 1,225 1,019 680
Net Nonoperating Obligations (NNO)		 330 1,178 7,808 5,178 46,204 45,999 53,580 46,988 44,083 42,781 48,873
Total Depreciation and Amortization (D&A)		 1,519 1,487 1,573 1,560 1,670 1,736 1,731 1,755 1,791 1,618 1,625
Debt-free, Cash-free Net Working Capital to Revenue		 -10.54% -2.43% -2.68% 1.79% -11.42% -3.24% -2.08% -0.41% -9.69% -5.50% -4.66%
Debt-free Net Working Capital to Revenue		 11.93% 19.00% 54.43% 65.57% 9.89% 18.49% 10.79% 16.36% 22.49% 22.22% 16.09%
Net Working Capital to Revenue		 9.02% 14.51% 49.35% 61.89% -7.49% 3.49% -10.87% 0.02% 11.57% 15.06% 9.36%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.88 $0.98 $0.41 ($0.42) ($0.59) $0.55 $0.01 $0.79 $0.07 $0.52 $0.51
Adjusted Weighted Average Basic Shares Outstanding		 5.61B 5.63B 5.65B 5.65B 5.64B 5.66B 5.67B 5.67B 5.66B 5.68B 5.69B
Adjusted Diluted Earnings per Share		 $0.86 $0.97 $0.41 ($0.42) ($0.59) $0.55 $0.01 $0.78 $0.07 $0.52 $0.51
Adjusted Weighted Average Diluted Shares Outstanding		 5.73B 5.73B 5.71B 5.65B 5.71B 5.70B 5.70B 5.71B 5.70B 5.71B 5.71B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.62B 5.65B 5.65B 5.65B 5.65B 5.67B 5.67B 5.67B 5.67B 5.69B 5.69B
Normalized Net Operating Profit after Tax (NOPAT)		 5,756 5,806 1,686 -2,111 -1,206 3,844 1,580 5,010 2,168 3,091 3,591
Normalized NOPAT Margin		 22.90% 31.41% 12.96% -15.65% -8.28% 25.83% 11.89% 28.30% 12.20% 22.54% 24.50%
Pre Tax Income Margin		 20.81% 33.92% 17.44% -24.85% -28.34% 22.99% -0.78% 26.64% -0.06% 20.31% 20.77%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 28.60% 31.06% 42.32% 87.23% 428.50% -3,387.64% -365.73% 220.52% 117.99% 121.04% 89.34%
Augmented Payout Ratio		 34.97% 31.06% 42.32% 87.23% 428.50% -3,387.64% -365.73% 220.52% 117.99% 121.04% 89.34%

Key Financial Trends

Pfizer Inc. (NYSE: PFE) has shown a generally positive financial trajectory over the past four years, with some variability in revenue and profitability that investors should be mindful of.

Key positive trends and highlights:

  • Steady increase in operating revenue from approximately $13.0 billion in Q2 2023 to about $14.7 billion in Q2 2025, reflecting consistent top-line growth.
  • Sustained gross profit margins, with gross profit consistently around $9.9 billion to $11.0 billion each quarter in recent periods, signaling effective cost control on revenue.
  • Net income recovered strongly from significant losses in late 2023 to steady profitability in 2024 and 2025, with Q2 2025 net income at approximately $2.93 billion compared to a loss in Q4 2023.
  • Cash flow from operating activities remains mostly positive, with a notable rebound to $2.33 billion in Q1 2025 contributing to financial flexibility.
  • Substantial cash and short-term investments on the balance sheet (around $13.3 billion as of Q2 2025), supporting strong liquidity.
  • Consistent dividend payments, with a quarterly dividend reaching $0.86 per share in Q2 2025, indicating shareholder return focus.
  • Reduction in restructuring charges and operating expenses compared to the trough periods, suggesting improving operational efficiency.

Neutral considerations:

  • Total assets and liabilities have remained relatively stable around $200-$220 billion, showing no major fluctuations in Pfizer’s capital structure.
  • Long-term debt levels have been steady in the range of $57 billion to $61 billion over recent quarters, indicating manageable leverage.
  • Weighted average shares outstanding remain consistent around 5.6 billion, showing limited dilution over the period.

Negative trends and risks:

  • The company reported a large net loss of approximately $3.36 billion in Q4 2023, driven by high operating expenses and restructuring charges, highlighting volatility in some quarters.
  • Large fluctuations in other income/expense, including a significant $2.36 billion net other expense in Q4 2024, which impairs operating income consistency.
  • Negative cash flow from operations recorded in Q2 2024 (-$1.78 billion) and Q2 2025 (-$0.58 billion), possibly from working capital changes impacting cash generation.
  • Large investing cash outflows in mid-2023, including acquisitions and investments, reaching up to $25 billion net outflow, which may affect financial flexibility if not accretive.
  • Elevated restructuring charges in earlier periods (e.g., $1.25 billion in Q2 2024), suggesting ongoing business realignments that could pressure margins.

Summary: Pfizer has demonstrated resilience and recovery following a difficult 2023, supported by growing revenues, improving net income, and strong cash positions. However, investors should monitor the impacts of volatile other income/expenses, investment activities, and any future restructuring costs that could affect quarterly earnings and cash flow generation. The company's strong dividend and liquidity profile are positives for income-focused investors.

08/28/25 10:28 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Pfizer's Financials

When does Pfizer's financial year end?

According to the most recent income statement we have on file, Pfizer's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Pfizer's net income changed over the last 10 years?

Pfizer's net income appears to be on an upward trend, with a most recent value of $8.06 billion in 2024, falling from $9.17 billion in 2014. The previous period was $2.16 billion in 2023. Check out Pfizer's forecast to explore projected trends and price targets.

What is Pfizer's operating income?
Pfizer's total operating income in 2024 was $12.41 billion, based on the following breakdown:
  • Total Gross Profit: $45.78 billion
  • Total Operating Expenses: $33.37 billion
How has Pfizer's revenue changed over the last 10 years?

Over the last 10 years, Pfizer's total revenue changed from $49.61 billion in 2014 to $63.63 billion in 2024, a change of 28.3%.

How much debt does Pfizer have?

Pfizer's total liabilities were at $124.90 billion at the end of 2024, a 9.0% decrease from 2023, and a 30.2% increase since 2014.

How much cash does Pfizer have?

In the past 10 years, Pfizer's cash and equivalents has ranged from $416 million in 2022 to $3.64 billion in 2015, and is currently $1.04 billion as of their latest financial filing in 2024.

How has Pfizer's book value per share changed over the last 10 years?

Over the last 10 years, Pfizer's book value per share changed from 11.31 in 2014 to 15.56 in 2024, a change of 37.6%.


Related Companies

This page (NYSE:PFE) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
What Are Some Strategies to Help Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel
NVIDIA's Worst Nightmare?
$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...
The Oxford Club | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Trump’s national nightmare is here
AI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...
Porter & Company | Sponsoredtc pixel